Medical Device Electronic Labeling Act

Summary of Bill: S. 4519 (119th Congress)

Purpose and intent

S. 4519 seeks to amend the Federal Food, Drug, and Cosmetic Act (FD&C Act) to expand the use of electronic labeling methods for certain medical devices. Specifically, the bill would authorize, under specified conditions, that required labeling for more devices may be made available solely by electronic means (e-labeling) rather than printed labeling. The overarching goal is to modernize labeling delivery, improve access to up-to-date information, and potentially reduce printing costs and distribution burdens for manufacturers, while ensuring that labeling remains readily accessible to consumers and healthcare professionals.

Key provisions and changes

• Expansion of e-labeling authority: The bill broadens the types of devices for which the required labeling can be provided exclusively through electronic means.
• Regulatory framework and conditions: While the exact text is not provided here, such changes typically require:
  • Clear rules on what constitutes “electronic labeling” (e.g., availability via the internet or a secure device-based portal).
  • Requirements for accessibility, including alternatives for individuals without reliable electronic access.
  • Verification and update mechanisms to ensure labeling remains current and accurate.
  • Provisions to address situations where electronic labeling may be temporarily unavailable (e.g., offline access, printed copies upon request).
• Safety and accuracy safeguards: Likely to include mandates that essential safety information, indications, contraindications, instructions, and any changes must be promptly updated and clearly accessible.
• Applicability to devices: The expansion would apply to additional devices beyond those currently allowed to rely on electronic labeling, subject to the bill’s specified criteria and regulatory standards.

Who or what would be affected

• Medical device manufacturers: Potentially expanded responsibility to provide and maintain electronic labeling, ensure accessibility, and implement systems for distributing updates.
• Healthcare providers and patients: Individuals who rely on device labeling for safe and effective use would gain easier access to current information via electronic means, while ensuring options exist for those needing non-electronic access.
• Federal regulatory programs: The Food and Drug Administration (FDA) would oversee implementation, enforcement, and any necessary rulemaking to harmonize with FD&C Act requirements and public health safeguards.

Procedural and timeline aspects

• Introduced in the Senate: May 13, 2026.
• Referral: Referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP) on introduction.
• Sponsorship: Co-sponsors include Jim Banks and John Hickenlooper.
• Next steps: The bill would proceed through HELP committee consideration, potential markup, and, if reported, advancement to the full Senate for consideration. Any changes would later need to pass the House of Representatives (if not parallelly pursued) and be signed by the President to become law.

Notes and considerations

• The move to broader e-labeling aligns with broader federal efforts to digitize information and improve access, but practical considerations include ensuring equity of access, maintaining data integrity, and mitigating situations where electronic systems fail or are inaccessible.
• The bill’s final form could include explicit protections for patients who lack reliable electronic access and specific timelines for when e-labeling must be implemented for newly regulated devices.

If you’d like, I can tailor this summary to focus on potential impacts for manufacturers, healthcare systems, or patients, or compare with current FDA labeling rules relevant to electronic labeling.